Bardy Diagnostics

Hillrom has reached a definitive agreement to acquire Bardy Diagnostics, a provider of ambulatory cardiac monitoring technologies, for $375 million in cash plus potential milestone payments. The deal includes net operating losses valued at over $20 million.